Roflumilast improves lung function after 6 months compared with placebo

Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease (COPD) after 6 months of treatment compared with placebo.

Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with and a history of exacerbations.

To examine the drug's impact on lung function, researchers from multiple institutions, including Baylor College of Medicine; Takeda Pharmaceuticals International GmbH; and Forest Research Institute, randomized 4,746 subjects to roflumilast (pooled intent-to-treat [ITT], n= 2511; moderate COPD, n=1184; severe COPD, n=1217) or placebo (pooled ITT, n=2235; moderate COPD, n=1098; severe COPD, n=1062).

Baseline demographics were similar between treatment groups.

At 6 months, roflumilast increased pre- and postbronchodilator FEV1 by 66 mL and 67 mL, respectively, compared with placebo. Roflumilast, compared with placebo, also increased pre- and postbronchodilator in subjects with moderate and severe COPD.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

add to favorites email to friend print save as pdf

Related Stories

COPD readmission may be tied to unmodifiable risk factors

Oct 22, 2012

National efforts are underway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD); however, new research suggests that COPD readmissions may be related to risk factors that cannot be modified, including ...

Recommended for you

Experts want restrictions on testosterone drug use (Update)

22 hours ago

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments